Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

Abstract

This study determined the utility of a panel of serum fibrosis markers along with routine laboratory tests in estimating the likelihood of histological cirrhosis in a cohort of prior nonresponders with chronic hepatitis C. The relationship between serum markers and quantitative hepatic collagen content was also determined. Liver biopsy samples from 513 subjects enrolled in the HALT-C trial were assigned Ishak fibrosis scores. The collagen content of 386 sirius-red stained, nonfragmented biopsy samples was quantified using computerized morphometry. Serum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), amino-terminal peptide of type III procollagen (PIIINP), hyaluronic acid (HA), and YKL-40 levels were determined using commercially available assays.Sixty-two percent of patients had noncirrhotic fibrosis (Ishak stage 2-4) whereas 38% had cirrhosis (

Quantification of portal–bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C

“…[15][16][17][18][19][20][21][22][23][24] Notably, all these aforementioned studies used an interactive threshold to select fibrosis-related pixels that is time consuming for the operator and a possible source of intra-and interobserver variability. Moreover, none of these studies sought to determine the fibrosis ratio according to its topography in the liver tissue.…”

Fibrosis 4 Score Versus Hyaluronic Acid as Non-Invasive Tools for Assessment of HCV-Related Hepatic Fibrosis: Correlation with Quantitative Morphometric Analysis of Liver Biopsy

“…Morphometry was found to be more sensitive than histological staging in diagnosing fibrosis progression. Several studies postulate that morphometry is a reproducible, can detect early as well as advanced fibrosis or cirrhosis, and more precise for monitoring fibrosis progression or regression during clinical therapeutic trials [25][26][27].…”

Karaciğer Fibrozisinin İnvazif Olmayan Dolaylı Biyokimyasal Belirteçleri

“…FibroTest bu verileri bir araya getiren ilk algoritmadır 18 . Sonrasında başka skorlama sistemleri de önerilmiştir [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] ki bunlardan dördünün formülü ilgili patent şartları gereği ticari bir sır konumundadır.…”